Search / Trial NCT00002331

The Safety and Effectiveness of Clarithromycin Plus Ethambutol Used With or Without Clofazimine in the Treatment of MAC in Patients With AIDS

Launched by ABBOTT · Aug 30, 2001

Trial Information

Current as of December 26, 2024

Completed

Keywords

Mycobacterium Avium Intracellular Infection Drug Therapy, Combination Ethambutol Clofazimine Acquired Immunodeficiency Syndrome Clarithromycin

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria
  • Patients must have:
  • History of HIV seropositivity.
  • Disseminated MAC.
  • Positive blood culture for MAC within 4 weeks prior to study entry.
  • Consent of parent or guardian if less than 18 years of age.
  • Ability to complete the study.
  • NOTE:
  • Patients with active opportunistic infections other than dMAC are permitted if dosage and clinical parameters have been stable for 4 weeks prior to enrollment.
  • Exclusion Criteria
  • Concurrent Medication:
  • Excluded:
  • Active therapy with carbamazepine or theophylline, unless investigator agrees to carefully monitor blood levels.
  • Active therapy with investigational drugs other than treatment for HIV disease, except with approval of the sponsor.
  • Concomitant terfenadine (Seldane or Seldane-D) or astemizole (Hismanal).
  • Amikacin.
  • Azithromycin.
  • Capreomycin.
  • Ciprofloxacin.
  • Cycloserine.
  • Ethionamide.
  • Gentamicin.
  • Kanamycin.
  • Levofloxacin.
  • Lomefloxacin.
  • Ofloxacin.
  • Rifampin.
  • Rifabutin.
  • Sparfloxacin.
  • Streptomycin.
  • Any other aminoglycosides, quinolones, and macrolides.
  • Patients with the following prior conditions are excluded:
  • History of allergy or hypersensitivity to macrolides, ethambutol, or clofazimine.
  • Prior Medication:
  • Excluded:
  • Other antimycobacterials, including aminoglycosides, ansamycin (rifabutin), other macrolides (such as clindamycin), quinolones, and rifampin, between screening and study entry.
  • Clarithromycin or azithromycin as prophylaxis or treatment (for any cause) for more than 14 days cumulative within the past 2 months.

About Abbott

Abbott is a global healthcare company dedicated to improving lives through innovative medical technologies, diagnostics, nutrition, and branded generic pharmaceuticals. With a commitment to advancing health and wellness, Abbott conducts clinical trials to evaluate the safety and efficacy of its diverse portfolio of products, which span multiple therapeutic areas, including cardiovascular, diabetes care, and neurology. The company employs rigorous research methodologies and collaborates with healthcare professionals and institutions worldwide to ensure the highest standards of clinical integrity and patient safety. Abbott's mission is to deliver impactful solutions that enhance patient outcomes and contribute to the advancement of global healthcare.

Locations

New York, New York, United States

New York, New York, United States

Houston, Texas, United States

Chicago, Illinois, United States

New Orleans, Louisiana, United States

Baltimore, Maryland, United States

Sacramento, California, United States

Washington, District Of Columbia, United States

Los Angeles, California, United States

Dallas, Texas, United States

Chapel Hill, North Carolina, United States

San Francisco, California, United States

Tampa, Florida, United States

San Jose, California, United States

Miami, Florida, United States

Philadelphia, Pennsylvania, United States

Nashville, Tennessee, United States

Condado San Juan, , Puerto Rico

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials